102 related articles for article (PubMed ID: 8448632)
1. Monotherapy in rheumatoid arthritis.
Emery P
Br J Rheumatol; 1993 Mar; 32 Suppl 1():21-3. PubMed ID: 8448632
[TBL] [Abstract][Full Text] [Related]
2. Approaches to the management of rheumatoid arthritis: rationale for early combination therapy.
Wilske KR
Br J Rheumatol; 1993 Mar; 32 Suppl 1():24-7. PubMed ID: 8448633
[TBL] [Abstract][Full Text] [Related]
3. The need for aggressive therapy of rheumatoid arthritis.
Wilske KR; Healey LA
Rheum Dis Clin North Am; 1993 Feb; 19(1):153-61. PubMed ID: 8356250
[TBL] [Abstract][Full Text] [Related]
4. [The role of disease-modifying antirheumatic drugs (DMARDs) in the therapy of rheumatoid arthritis].
Cervini C; Salaffi F; Peroni M
Clin Ter; 1993 Jan; 142(1):3-18. PubMed ID: 8472508
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
6. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
7. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Julkunen H; Luukkainen R; Vuori K; Paimela L; Blåfield H; Hakala M; Leirisalo-Repo M
Arthritis Rheum; 2004 Jan; 50(1):55-62. PubMed ID: 14730599
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of efficacy and tolerability of triple combination therapy (methotrexate + sulfasalazine + hydroxychloroquine) with methotrexate monotherapy in patients with rheumatoid arthritis].
Gubar' EE; Bochkova AG; Bunchuk NV
Ter Arkh; 2008; 80(5):25-30. PubMed ID: 18590110
[TBL] [Abstract][Full Text] [Related]
9. [New perspectives in the treatment of rheumatoid arthritis].
Guzmán L
Rev Med Chil; 1993 Jul; 121(7):789-90. PubMed ID: 8296084
[TBL] [Abstract][Full Text] [Related]
10. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
[TBL] [Abstract][Full Text] [Related]
11. Overview of combination second-line or disease-modifying antirheumatic drug therapy in rheumatoid arthritis.
Williams HJ
Br J Rheumatol; 1995 Nov; 34 Suppl 2():96-9. PubMed ID: 8535657
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy of rheumatoid arthritis].
Hansen A; Jensen T
Ugeskr Laeger; 1998 Sep; 160(40):5772-6. PubMed ID: 9782754
[TBL] [Abstract][Full Text] [Related]
14. DMARDs in the treatment of rheumatoid arthritis: current agents and future developments.
Simon LS
Int J Clin Pract; 2000 May; 54(4):243-9. PubMed ID: 10912314
[TBL] [Abstract][Full Text] [Related]
15. [Sulfasalazine: side effects and duration of therapy in patients with rheumatoid arthritis].
Mundo A; Pedone V; Lamanna G; Cervini C
Clin Ter; 1997; 148(1-2):7-13. PubMed ID: 9377840
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic strategies in rheumatoid arthritis over a 40-year period.
Kremers HM; Nicola P; Crowson CS; O'Fallon WM; Gabriel SE
J Rheumatol; 2004 Dec; 31(12):2366-73. PubMed ID: 15570636
[TBL] [Abstract][Full Text] [Related]
17. [Clinical pharmacology of nonsteroidal anti-inflammatory agents. III: Principles of therapeutic use].
Reinicke C
Z Arztl Fortbild (Jena); 1985; 79(12):515-22. PubMed ID: 3929483
[No Abstract] [Full Text] [Related]
18. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
19. Modern drug treatment options for rheumatoid arthritis.
Binning M
Aust Nurs J; 2001 Apr; 8(9):suppl 1-3. PubMed ID: 11894377
[No Abstract] [Full Text] [Related]
20. [Pharmacologic therapy of rheumatoid arthritis with delayed-action anti-rheumatic drugs].
Saal JG
Internist (Berl); 1993 Jan; 34(1):9-17. PubMed ID: 8440581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
